1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

EU Accelerated Assessment Tracker: Rejection Is Standard Outcome For Fast-Track Requests This Year

 
• By Maureen Kenny and Neena Brizmohun

Attempts by companies to have their investigational products fast-tracked through the EU approval system this year so far have largely failed. Often the same products have or had priority review in the US. With the European Medicines Agency deciding on four new accelerated assessment requests this week, will the tide start to turn?

Row of pencil tops enter on an angle from bottom right with erasers flush and pointing toward center. Seventh pencil in stands out with sharpened lead tip jutting out further than adjacent erasers.
Fast-Track Status Can Give Companies The Edge Over Competitors

Just one of the seven requests for accelerated assessment that the European Medicines Agency has processed this year is known to have been successful. One request has been granted, four have been denied and the outcomes of two are unknown.

Decisions are due to be taken on a further four requests this week. Also see " New EU Speedy Review Hopefuls: Novimmune, AveXis, bluebird bio, and Loxo Oncology "...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

UroGen’s Mitomycin: Are Randomized Trials For Bladder Cancer Necessary?

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee will vote on the risk-benefit of UGN-102 for low-grade, intermediate-risk, non-muscle invasive bladder cancer based on data from a single-arm trial, but the FDA also seeks input on requiring randomized studies for future treatments.

Life After Loper: Vaping Case Shows US FDA Retains Considerable Deference

 
• By Craig Bleifer, Royce DuBiner, Max Bogost, Michael Brody, and Allyson Maur

A US Supreme Court ruling in favor of the agency in an e-cigarette case has implications for drugs and other medical products as the justices decided not to disturb the FDA’s ‘change in position’ authority, while also creating a complex new landscape.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.